IMFINZI (durvalumab) Approved for Previously Treated Patients with Advanced Bladder Cancer, available immediately at Biologics, Inc.

CARY, N.C. (May 22, 2017) — Biologics, Inc., a McKesson Specialty Health oncology pharmacy services company, has been selected by AstraZeneca to be a specialty pharmacy provider in the limited distribution network for IMFINZITM (durvalumab). In addition to being available via specialty distribution,...
Source: McKesson News - Category: Information Technology Source Type: news